Other News To Note

• Intellect Neurosciences Inc., of New York, and MRC Technology, of London, said they completed humanization of 82E1, a mouse monoclonal antibody to create a high-affinity stabilized IgG4 therapeutic antibody that binds the amino terminus of amyloid beta without binding to the amyloid precursor protein.